• LAST PRICE
    0.0350
  • TODAY'S CHANGE (%)
    Trending Down-0.0150 (-30.0000%)
  • Bid / Lots
    0.0350/ 316
  • Ask / Lots
    0.0400/ 10
  • Open / Previous Close
    0.0450 / 0.0500
  • Day Range
    Low 0.0350
    High 0.0500
  • 52 Week Range
    Low 0.0350
    High 0.2500
  • Volume
    205,670
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.05
TimeVolumeFH
09:36 ET410000.045
10:32 ET20000.045
11:47 ET190000.045
12:54 ET30000.045
02:20 ET10000.05
02:47 ET150000.04
02:49 ET990000.035
03:21 ET150000.04
03:52 ET100000.04
03:59 ET00.035
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
CanadaFH
Filament Health Corp
7.1M
-0.4x
---
CanadaMYTC
MyndTec Inc
6.0M
-3.3x
---
CanadaIZO
Izotropic Corp
6.9M
-1.4x
---
CanadaTHRM
Therma Bright Inc
6.3M
-1.4x
---
CanadaOKAI
EvokAI Creative Labs Inc
10.3M
-1.5x
---
CanadaSCYB
Scryb Inc
7.7M
-0.6x
---
As of 2024-03-29

Company Information

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral delivery (1mg and 25mg), PEX020 Psilocin - oral delivery (dose withheld), and PEX030 Psilocin - sublingual delivery (dose withheld). The Company's preclinical stage drug candidates include AEX010 Ayahuasca - oral delivery (dose withheld), and AEX020 Monoamine Oxidase Inhibitor - oral delivery (dose withheld). The Company’s internal drug discovery and development program is carried out by its wholly owned subsidiary, Psilo Scientific Ltd., and is focused on developing standardized pharmaceutical-grade drug candidates from botanical psychedelic biomass.

Contact Information

Headquarters
210-4475 Wayburne DriveBURNABY, BC, Canada V5G 4X4
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Gregory Mills
Chief Executive Officer, Director
Benjamin Lightburn
Chief Financial Officer
Warren Duncan
Corporate Secretary, Director
Jon Conlin
Independent Director
Maureen Oconnell

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.1M
Revenue (TTM)
$570.0K
Shares Outstanding
202.7M
Filament Health Corp does not pay a dividend.
Beta
---
EPS
$-0.09
Book Value
$0.02
P/E Ratio
-0.4x
Price/Sales (TTM)
12.4
Price/Cash Flow (TTM)
---
Operating Margin
-2,815.78%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.